SCINAI IMMUNOTHERAPEUTICS LTD. Stock-Based Compensation
SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) reported Stock-Based Compensation of $303.00 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-04-01
- SCINAI IMMUNOTHERAPEUTICS LTD. share-based payment arrangement, noncash expense for the quarter ending 2023-06-30 was $200.00K, a 48.05% decline year-over-year.
- SCINAI IMMUNOTHERAPEUTICS LTD. share-based payment arrangement, noncash expense for the quarter ending 2023-03-31 was $252.00K, a 48.04% decline year-over-year.
- SCINAI IMMUNOTHERAPEUTICS LTD. share-based payment arrangement, noncash expense for the quarter ending 2022-06-30 was $385.00K.
- SCINAI IMMUNOTHERAPEUTICS LTD. share-based payment arrangement, noncash expense for the quarter ending 2022-03-31 was $485.00K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|
| 2025-12-31 | $303.00K 20-F · filed 2026-04-01 | ||
| 2025-06-30 | $270.00K 6-K · filed 2025-09-02 | ||
| 2024-12-31 | $682.00K 20-F · filed 2026-04-01 | ||
| 2024-06-30 | $333.00K 6-K · filed 2025-09-02 | ||
| 2023-12-31 | $1.14M 20-F · filed 2026-04-01 | ||
| 2023-06-30 | $200.00K derived: 6-K 6 month − 10-Q 3 month · filed 2024-09-09 | $452.00K 6-K · filed 2024-09-09 | |
| 2023-03-31 | $252.00K 10-Q · filed 2023-05-15 | ||
| 2022-12-31 | $1.60M 20-F · filed 2025-05-07 | ||
| 2022-06-30 | $385.00K derived: 6-K/A 6 month − 10-Q 3 month · filed 2023-08-18 | $870.00K 6-K/A · filed 2023-08-18 | |
| 2022-03-31 | $485.00K 10-Q · filed 2023-05-15 | ||
| 2021-12-31 | $2.76M 20-F · filed 2024-05-15 |